Breaking News Instant updates and real-time market news.

CYAD

Celyad

$12.60

-0.7 (-5.26%)

12:27
07/05/19
07/05
12:27
07/05/19
12:27

Celyad target lowered to $48 on new launch timeline at H.C. Wainwright

H.C. Wainwright analyst Edward White lowered his price target for Celyad to $48 from $52 after Celyad presented updates on CYAD-01 and CYAD-101. Both studies showed disease control with patients exhibiting partial response and stable disease, White tells investors in a research note. And importantly, both therapies were well tolerated as there were no reports of cytokine syndrome release Grade 2 or higher, and no serious adverse events, dose-limiting toxicities nor on-target off-tumor toxicity, adds the analyst. The analyst trimmed his price target after moving back his launch expectation for CYAD-01 to 2024. White keeps a Buy rating on the shares.

  • 05

    Jul

  • 30

    Jul

CYAD Celyad
$12.60

-0.7 (-5.26%)

07/05/19
PIPR
07/05/19
NO CHANGE
Target $25
PIPR
Overweight
Celyad price target lowered to $25 from $41 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Celyad to $25 from $41 after the company presented preliminary interim data from the ongoing SHRINK and alloSHRINK Phase 1 trials of the NKG2D-based CAR-T therapies CYAD-01 and CYAD-101 for the treatment of metastatic colorectal cancer at the European Society for Medical Oncology Congress. He believes Celyad will prioritize development of an allogeneic CAR-T in solid tumors given there was no clinical evidence of Graft versus Host Disease and anticipates the next alloSHRINK update by year-end 2020. Tenthoff cites pushing out approval expectations for his lowered price target, but keeps an Overweight rating on Celyad shares.
06/17/19
RHCO
06/17/19
NO CHANGE
RHCO
Celyad selloff a buying opportunity, says SunTrust
SunTrust analyst Peter Lawson reiterated a Buy rating and $45 price target on Celyad after the stock dropped by almost 29% post-EHA, or European Hematology Association. The analyst sees this as a buying opportunity, as he believes it is undervalued, and also believes the year-end data is more important to the stock than the current headline data, which he said is "too early" and doesn't warrant a selloff.
06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper Jaffray reiterates Overweight on Celyad after EHA update
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $41 price target on Celyad after the company presented updated data for Phase I THINK and DEPLETHINK at the European Hematology Association, or EHA. Tenthoff noted that the updated Phase I THINK study now shows 4/13, or 31%, evaluable r/r AML patients achieved objective responses on CYAD-01 monotherapy without preconditioning with manageable safety, while the Phase I DEPLETHINK study demonstrated 2/5 evaluable patients achieved SD on CYAD-01 with pre-conditioning regiment of cyclphosphamide and fludarabine at the same three dose level as in THINK. The analyst added that Celyad could potentially initiate a registrational Phase II AML study in the second half of the year.
04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Celyad price target lowered to $41 from $51 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Celyad, but lowered his price target on shares to $41 from $51 as he pushes out approvals based on clinical progress. The analyst noted that Celyad intends to initiate a potentially registrational Phase II AML study in the second half of 2019, has begun a Phase I study of allogeneic CYAD-101 in mCRC with data in the second half of 2019, and will file INDs on CYAD-211 BCMA and CYAD-221 CD-19 CAR-Ts in 2020.

TODAY'S FREE FLY STORIES

RM

Regional Management

$26.62

-0.28 (-1.04%)

16:20
07/16/19
07/16
16:20
07/16/19
16:20
Hot Stocks
Regional Management appoints Robert Beck CFO »

Regional Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/16/19
07/16
16:20
07/16/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 16th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$15.54

-0.65 (-4.01%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Whiting Petroleum names Correne S. Loeffler CFO »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 27

    Aug

UAL

United Continental

$94.00

2.7 (2.96%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Breaking Hot Stocks news story on CSX »

CSX Q2 CapEx down to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

BPMX

BioPharmX

$0.44

-0.0183 (-3.97%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
BioPharmX appoints Steven Bosacki COO »

BioPharmX Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCCL

China Ceramics

$0.87

(0.00%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
China Ceramics receives Nasdaq notification of non-compliance »

China Ceramics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
United Continental reports Q2 total passenger revenue up 6.1% y/y »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VNDA

Vanda Pharmaceuticals

$13.45

-0.13 (-0.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Vanda Pharmaceuticals announces study results for tradipitant »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

, UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Recommendations
Neuronetics, UnitedHealth analyst commentary  »

UnitedHealth coverage…

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
Cintas sees FY20 EPS $8.30-$8.45, consensus $8.32 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
United Continental raises FY19 adj. EPS view to $10.50-$12.00, consensus $11.33 »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Earnings
Cintas reports Q4 EPS ex-items $2.07, consensus $1.93 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
CSX says merchandise growth 'offset' intermodal weakness »

Chemicals increased as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PETX

Aratana Therapeutics

$4.94

-0.11 (-2.18%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
Aratana Therapeutics shareholders vote to adopt merger with Elanco Animal Health »

Aratana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

KSFTF

Kingsoft

$0.00

(0.00%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Downgrade
Kingsoft rating change  »

Kingsoft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.68

1.16 (1.48%)

16:13
07/16/19
07/16
16:13
07/16/19
16:13
Hot Stocks
CSX reports Q2 operating ratio fell to 57.4% since Q2 last year »

Last year's Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PDD

Pinduoduo

$20.13

0.77 (3.98%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Pinduoduo rating change  »

Pinduoduo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCBS

Nicolet Bankshares

$62.76

0.13 (0.21%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Earnings
Nicolet Bankshares reports Q1 EPS $1.91 with items, consensus $1.09 »

During Q2, Nicolet sold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$41.65

-1.39 (-3.23%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$36.88

-0.47 (-1.26%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Upgrade
Ctrip rating change  »

Ctrip upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.67

1.15 (1.46%)

16:11
07/16/19
07/16
16:11
07/16/19
16:11
Hot Stocks
CSX falls 6% after reporting Q2 results below expectations »

CSX shares are trading at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.